105601-04-5 | 3-[1-(Dimethylamino)ethyl]phenol

Packsize	Purity	Availability	Price	Discounted Price
250mg	97%	in stock	$16.00	$11.00
1g	97%	in stock	$19.00	$13.00
5g	97%	in stock	$33.00	$23.00
25g	97%	in stock	$73.00	$51.00
100g	97%	in stock	$201.00	$141.00
500g	97%	in stock	$665.00	$466.00

Description

• Catalog Number: AI06775
• Chemical Name: 3-[1-(Dimethylamino)ethyl]phenol
• CAS Number: 105601-04-5
• Molecular Formula: C10H15NO
• Molecular Weight: 165.2322
• MDL Number: MFCD08272688
• SMILES: CN(C(c1cccc(c1)O)C)C

Computed Properties

• Complexity: 136
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 12
• Hydrogen Bond Acceptor Count: 2
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 2
• Undefined Atom Stereocenter Count: 1
• XLogP3: 1.8

Upstream Synthesis Route

The 3-(1-(Dimethylamino)ethyl)phenol compound has found significant utility in chemical synthesis as a versatile building block. Its unique structure combines a phenol group with a dimethylaminoethyl moiety, enabling it to participate in a variety of synthetic reactions. This compound can serve as a precursor in the synthesis of various pharmaceuticals, agrochemicals, and specialty chemicals. Its ability to undergo different functional group transformations makes it a valuable intermediate in the production of diverse organic compounds. Additionally, the presence of the phenol group allows for further derivatization, expanding the range of potential applications in organic synthesis.

Literature

• Simultaneous determination of antidementia drugs in human plasma: procedure transfer from HPLC-MS to UPLC-MS/MS.

  Journal of pharmaceutical and biomedical analysis 20120501

• Concentrations of rivastigmine and NAP 226-90 and the cognitive response in Taiwanese Alzheimer's disease patients.

  Journal of Alzheimer's disease : JAD 20120101

• Spectrophotometric and spectrodensitometric methods for the determination of rivastigmine hydrogen tartrate in presence of its degradation product.

  Drug testing and analysis 20100501

• Simultaneous determination of galantamine, rivastigmine and NAP 226-90 in plasma by MEKC and its application in Alzheimer's disease.

  Electrophoresis 20090201

• Pharmacokinetics and bioavailability of the novel rivastigmine transdermal patch versus rivastigmine oral solution in healthy elderly subjects.

  Journal of clinical pharmacology 20080201

• Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients.

  Clinical pharmacology and therapeutics 20080101

• Steady-state pharmacokinetics of rivastigmine in patients with mild to moderate Alzheimer's disease not affected by co-administration of memantine: an open-label, crossover, single-centre study.

  Clinical drug investigation 20080101

• [Synthesis of S-(+)-rivastigmine hydrogentartrate].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20070201

• A simple and sensitive assay for the quantitative analysis of rivastigmine and its metabolite NAP 226-90 in human EDTA plasma using coupled liquid chromatography and tandem mass spectrometry.

  Rapid communications in mass spectrometry : RCM 20060101

• A stability indicating LC method for rivastigmine hydrogen tartrate.

  Journal of pharmaceutical and biomedical analysis 20050207

• A simple, rapid and sensitive method for simultaneous determination of rivastigmine and its major metabolite NAP 226-90 in rat brain and plasma by reversed-phase liquid chromatography coupled to electrospray ionization mass spectrometry.

  Biomedical chromatography : BMC 20040401

• Kinetic and structural studies on the interaction of cholinesterases with the anti-Alzheimer drug rivastigmine.

  Biochemistry 20020319